The ECB should lower interest rates further if economic expansion falls short of forecasts and drags down inflation excessively, according to Governing Council member Fabio Panetta https://t.co/9bjWBXWDqV ...

How quickly can things swing back when everyone is short dollar right now. Well, that is something the electorate has always have to take into account, right. The positioning can mean that the moves don't go the way that you would normally expect them to be.And and, you know, there are various things that could get us into a situation where the dollar maybe starts to behave more like a haven again and we see more cash flowing back into the US or in a very good news situation for the US as well. Likewise, th ...

RT Mel Mattison (@MelMattison1)MMT 101: You finance the gov't at ultra-low short-term rates. This keeps interest expense as % of GDP in check even as overall debt levels rise. Other reasons: HELOCs tied to SOFR, wants to unlock $12T+ in home equity to juice economy. Corporates can issue floaters, also tied to short-term rates. I could go on. But feel it somewhat pointless as all people want to do is claim some sort of intellectual superiority to DJT rather than see the driving force behind his motivations. ...

Trade and Tariffs - The Trump administration is issuing tariff demand letters, totaling 22 letters so far, to ignite negotiations with some nations and political standoffs with others [1] - Brazil was hit with a 50% tariff, leading to political tensions as the Brazilian president views it as a political message [1][15] - The market is uncertain about tariffs, with only a handful of deals signed and details obscured; many countries are under pressure to deliver concessions to the U S by August 1 to avoid higher tariffs [1] - The U S has already collected billions of dollars in tariffs, estimated to reach around $300 billion by the end of the year, which is a little over 1% of the U S economy [41] - The market does not fully believe President Trump's statements about tariffs, and uncertainty around trade policy remains high [11][12] - The negative effects of tariffs may not be as bad as initially priced into the market, but the top-line benefits promised may not materialize [5][13] - The most important trade deal for the White House to present is with Europe, given its status as the largest investor in the U S and the complexity of needing approval from 20 different countries [21][22] Market and Economic Impact - Tech stocks, industrial stocks, and NASDAQ are at record highs, with NVIDIA up 40% since Trump tariffs [2] - The S&P 500 closed at a record high, while industrial stocks were less than 1% from achieving a record high [4] - Market gains are primarily driven by big tech companies like Microsoft, Amazon, and NVIDIA [6][7] - Smaller companies in the Russell 2000 and S&P 500 mid-caps are struggling and not near record highs, indicating a lack of broadening in the rally [8] - Imports to the U S represent roughly 13%-14% of GDP, with only a small portion covered by tariffs so far, making the impact visible but not necessarily prominent [15] - The uncertainty surrounding tariffs is making the Federal Reserve wary of cutting rates too quickly [17] Geopolitics and Policy - Secretary of State Marco Rubio met with his Russian counterpart to express disappointment with Vladimir Putin over attacks on Ukraine [1][23] - American-made weapons have resumed shipments to Ukraine, including artillery shells and mobile rocket artillery missiles [29] - The U S has not given Ukraine any U S F-16s but has okayed allies to do so [34] - The Justice Department has opened criminal investigations into former FBI Director James Comey and former CIA Director John Brennan [23] - A federal judge in New Hampshire blocked President Trump's effort to limit automatic birthright citizenship, reinstating protections that were paused last month [71] Agriculture - For American farmers, President Trump's tariff policy is a mixed bag [50] - Corn prices are under $4, and soybean prices are under $10, reflecting a market with a surplus and a lack of demand [51] - China did not meet the goals and requirements of the Phase One agreement during the first Trump administration [51] - The U S agriculture relies on several hundred thousand farmworkers, primarily in specialty crop and dairy areas [54] - Changes to the SNAP program could reduce farm income, as $020 of every food dollar spent at a grocery store ultimately ends up with a farmer [63]

Peru kept interest rates unchanged as its economy comes under threat from Donald Trump’s plan for a 50% copper tariff https://t.co/w9m3o3gMKc ...

Core Insights - The current economic environment favors well-capitalized and growth-oriented companies, which are outperforming their counterparts in the U.S. market [1] - A structural shift in the U.S. market is indicated by the sustained outperformance of large-cap and growth securities over small-cap and value stocks [2] - The S&P 500 Growth Index has returned 15.46% over the past year, significantly outperforming the S&P 500 Value Index, which gained 8.85% [3] - Barclays maintains a positive outlook on U.S. growth stocks due to strong earnings momentum and lower leverage risk associated with large-cap securities [4] Market Sentiment - Bank of America and Goldman Sachs have raised their year-end forecasts for the S&P 500, with BofA increasing its target to 6,300 and Goldman to 6,600, reflecting a bullish sentiment [5] - Citigroup, Barclays, and Deutsche Bank have also raised their year-end targets for the S&P 500, indicating growing optimism in the U.S. equity market [6] - The S&P 500 has gained approximately 6.7% year-to-date, with a significant rally following a pause on tariffs announced by President Trump [6] Investment Opportunities - Large-cap ETFs are recommended for investors seeking exposure to the improving market outlook, particularly in the tech sector driven by the AI boom [7] - Notable large-cap ETFs include Vanguard S&P 500 ETF (VOO), SPDR S&P 500 ETF Trust (SPY), and iShares Core S&P 500 ETF (IVV), with VOO having the largest asset base of $689.85 billion [8] - Growth-focused ETFs such as Vanguard Growth ETF (VUG) and iShares Russell 1000 Growth ETF (IWF) are highlighted for investors looking to capitalize on the shift in market sentiment [11][12] - VUG has an asset base of $175.61 billion, making it the largest among growth-focused options, with annual fees of 0.04% for SPYG, VUG, and IUSG, suitable for long-term investing [13]

Market & Policy Landscape - Markets favor certainty, and with the budget resolved and some tariff issues addressed, the environment is becoming clearer [3][4] - The venture market is showing signs of renewed liquidity after four years of stagnation, driven by a more friendly FTC, encouraging IPOs and M&A [5] - Tech regulation primarily occurs at the state level, often overlooked in favor of federal politics [9] Crypto & Digital Assets - The market momentum of crypto makes it difficult to assess using traditional logic [11] - The acceptance of crypto by the federal government, including banks' involvement in stablecoins, raises questions about future growth potential [12] - Proactive positive movements by the SEC and the White House on crypto suggest further bullish potential [13] Regulatory Environment & Industry-Specific Issues - Deregulation by the Trump administration could resolve regulatory issues, contrasting with the hands-off approach of the Biden administration [8] - The Genius Act, a stable coin act, has passed the Senate but awaits House approval, with the market potentially pricing it in [6] - Autonomous trucking faces regulatory hurdles, with the US DOT yet to issue sensible interstate regulations [8]

Core Points - Nu Holdings' shares fell 4.5% to close at $13.03 on July 10, with a trading volume of approximately 107.8 million shares, which is about 79% above its 50-day average volume of 60.1 million shares [1] - The decline occurred despite broader market gains, with the S&P 500 up 0.27% and the Dow Jones Industrial Average up 0.43%, while competitor SoFi Technologies rose 3.7% [2] - Nu Holdings remains above its 50-day ($12.64) and 200-day ($12.49) moving averages, with a year-to-date gain of approximately 25.8%, indicating a longer-term upward trend [3] - The decline may be attributed to multiple factors, including potential growth slowdown, inflation concerns, and rising interest rates in Latin America, with increased trading volume suggesting institutional repositioning or profit-taking [3]

the politics around capitalism or a rigged system also matter and have only gotten more significant. You went off on this on this very channel on these airwaves about this combination and I say this in the context of a Democratic party that is increasingly looking at alternatives to actual capitalism even though that sounds radical to some people. We saw that in New York primary. Uh let's take a look at what you said. An entire integrated system, financial system, trading system, taxing system that was crea ...

Core Points - Crinetics Pharmaceuticals granted non-qualified stock option awards for 102,350 shares and restricted stock unit (RSU) awards for 77,875 shares to 46 new non-executive employees as part of the 2021 Employment Inducement Incentive Award Plan [1][2] - The stock options have an exercise price of $31.99 per share, equal to the closing price on July 10, 2025, and will vest over four years [2] - Crinetics Pharmaceuticals is focused on developing novel therapeutics for endocrine diseases and related tumors, with lead candidate paltusotine in clinical development for acromegaly and carcinoid syndrome [3] Summary by Category Stock Options and RSUs - The stock options and RSUs were granted as inducements for new employees under the 2021 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4) [1][2] - Stock options will vest 25% after one year, with the remainder vesting in 36 equal monthly installments, contingent on continued employment [2] - RSUs will vest in equal annual installments over four years, also dependent on continued employment [2] Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company specializing in endocrine diseases and tumors [3] - The company’s lead candidate, paltusotine, is the first investigational oral selective somatostatin receptor type 2 nonpeptide agonist [3] - Other drug candidates in development include treatments for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with a focus on orally delivered small molecules [3]